



Meda acquires product portfolio from the US pharma company Wyeth

- Meda is acquiring 10 well-established pharmaceutical products from Wyeth
- The products give Meda sales of about SEK 160-170 million for the remainder of 2007 (8 months)
- Meda's position is strengthened on key European markets such as Italy and France
- The purchase price is about SEK 525 million

Meda and the US pharma company Wyeth have reached an agreement regarding acquisition of 10 well-established pharmaceuticals in Europe. The agreement with Wyeth is one example of how we use our strong platform throughout Europe for profitable, marginal deals," says Anders Lönner, Meda's CEO.

The acquired products are highly recognised brands with good profitability. The effective date is 1 May 2007. No employees will transfer from Wyeth to Meda in conjunction with the acquisition, which is expected to inject sales of about SEK 160-170 million into Meda's operation for the remainder of 2007. The purchase price is about SEK 525 million, which will be totally financed via existing credit facilities.

Through the acquisition, Meda strengthens its position on two of its most important markets Italy and France. These countries account for about 60% of the acquired products' sales.

The largest acquired product is Seresta®, a central nervous system (CNS) drug with the active substance oxazepam. Oxazepam belongs to the benzodiazepine group of drugs and is an anti-anxiety agent used for sleep disorders and various substance-withdrawal syndromes. Meda already has three major CNS products: Imovane® (sleep disorders), Thiocticacid® (diabetic neuropathy), and Parlodel® (Parkinson's disease).

The majority of sales come from these acquired products:

<u>Active substance</u>	<u>Brand name</u>	<u>Medical use</u>	<u>Therapy area</u>
Oxazepam	Seresta®, Serpax®, Serenal®, Praxiten®	Anti-anxiety and tranquilizing agent (benzodiazepine)	Central nervous system (CNS)
Mitoxantron	Novantrone®, Elsep®, Ralenova®	Cancer and multiple sclerosis (MS)	CNS/cancer
Zaleplon	Sonata®, Zerene®	Sleep disorders	CNS
Lormetazepam	Loramet®	Anti-anxiety and tranquilizing agent (benzodiazepine)	CNS

For more information, contact

Anders Lönner, CEO	tel.	+46 8-630 19 72
Anders Larnholt, Investor Relations	tel.	+46 8-630 19 62, +46 709 458 878

MEDA AB (publ) is a leading European specialty pharma company that concentrates on marketing and marketadapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda has own affiliates in 24 countries and more than 1,000 employees within marketing and sales. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.

Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. Wyeth's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.